SEOUL, December 18 (AJP) - South Korea's Daesang Corp. said on Thursday it will enter the pharmaceutical biotechnology sector through the acquisition of AMINO GmbH, a German company specializing in pharmaceutical-grade amino acids.
In a regulatory filing, Daesang said it will acquire a 100 percent stake in AMINO for about 50.2 billion won ($36 million). The company said it is in the process of securing the necessary regulatory approvals and aims to complete the transaction by March 2026.
Founded in 1958, AMINO manufactures pharmaceutical amino acids used in intravenous solutions, clinical nutrition products and cell culture media, as well as excipients used in biopharmaceutical production. The company operates a research center and three manufacturing facilities in the Prellstedt area of northern Germany and supplies major global biopharmaceutical companies and medical nutrition specialists.
Daesang said the acquisition will allow it to enter the high-value pharmaceutical amino-acid market, citing steady growth in demand for IV solutions and patient nutrition. The company also pointed to rising demand for inputs linked to the growth of biopharmaceuticals, including protein-, gene- and cell-based therapies.
AMINO’s purification technology, manufacturing infrastructure and experience navigating European regulatory requirements are expected to be key assets as Daesang expands into pharmaceutical biotechnology, the company said.
“This acquisition is a strategic investment that enables Daesang to expand beyond its existing materials business into the high-value pharmaceutical biotech market,” CEO Lim Jung-bae said in a press release. “We will strengthen our competitiveness in pharmaceutical amino acids by leveraging AMINO’s technology and global network.”
Copyright ⓒ Aju Press All rights reserved.
